Overview

Pharmacokinetic Study of Tacrolimus and Mycophenolate Mofetil in Kidney Transplant Recipients With Hyperkalemia Receiving Patiromer

Status:
Completed

Trial end date:
2019-08-07

Target enrollment:

Participant gender:

Summary

Hyperkalemia (high potassium in blood) is a common condition found in kidney transplant patients. Risk factors include poor kidney function and exposure to various drugs. Regardless of the causes, current treatment options are limited. Previously, the only available potassium binder for lowering potassium in the blood is sodium polystyrene sulfonate, which has unknown drug interaction profile with transplant medications. Patiromer is a newly approved potassium binder indicated for the treatment of hyperkalemia. Kidney transplant patients with hyperkalemia may benefit from patiromer. However, the interaction of patiromer and transplant medications has not been studied. The goal of this study is to look into the drug interactions between patiromer and transplant medications.

Phase:

Phase 4

Details

Lead Sponsor:

The Rogosin Institute

Collaborator:

Weill Medical College of Cornell University

Treatments:

Mycophenolate mofetil
Mycophenolic Acid
Tacrolimus